Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

t of SEGA response rate, with 35% of patients (27 of 78) receiving everolimus experiencing a 50% or greater reduction in SEGA volume (sum of volumes of all target SEGAs) relative to baseline versus 0% of patients (0 of 39) on placebo (p<0.0001)(1).

"This study, which included SEGA patients from infancy to adulthood, provides compelling evidence of the impact of everolimus in reducing SEGA size with a tolerability profile consistent with the previous everolimus trial in this treatment setting," said Dr. Sergiusz Jozwiak, a lead EXIST-1 investigator and Professor, Department of Child Neurology, The Children's Memorial Health Institute, Warsaw, Poland. "This is very good news for patients and caregivers in many countries who currently may face brain surgery as the only treatment option for growing SEGAs."

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(9). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes. When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism, leading to the formation of non-cancerous tumors throughout the body, including the brain. By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation, blood vessel growth and glucose uptake related to SEGA associated with TSC(2,6).

"The positive results seen in the Phase III trial point to the important role of everolimus and mTOR inhibition in SEGA associated with TSC," said Herve Hoppenot, President, Novartis Oncology. "This outcome is welcome news as we continue our research efforts to fully understand the potential of this important treatment option across the wide range of disorders associated with TSC."

The Phase III study supports the findings of the Phase II study used for registration in s
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... ZIONA, Israel , June 29, ... BVXV, TASE: BVXV) today announced positive preliminary results from ... candidate for a universal influenza vaccine. In this trial, ... of 50 to 65, followed by an administration of ... later. M-001 was found to be safe and well ...
(Date:6/29/2015)... Calif. , June 29, 2015  Isis Pharmaceuticals, ... has been added to the Russell 1000 Index, effective ... performance of the large-cap segment of the U.S. equity ... Index and includes approximately 1000 of the largest securities ... current index membership. "We are pleased to ...
(Date:6/29/2015)... Calif. , June 29, 2015  Arbor ... medical workstation lineup. The high-powered, multi-functional M2150 ... generation Intel® Haswell Core i5-4402E 1.6 ... provide significant data processing and computing performance. Integrated ... making the unit well suited for graphics-intense applications ...
Breaking Medicine Technology:BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... , CHEYENNE, Wyo., Aug. 24 The ... of its Pay-for-Participation (P4P) program, a component of its innovative ... collaboration between the practitioner community and the Wyoming EqualityCare (EC) ... Wyoming Medicaid members. , , (Logo: ...
... Curemark Founder and CEO Dr. Joan Fallon delivered the ... Conference at Harvard Medical School on July 14th. , ... conclave is particularly significant, since epigenetics is the study of ... in the DNA sequence. Presenters at the session showcased many ...
Cached Medicine Technology:Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 2Wyoming Department of Health's Pay-for-Participation Program Reports Positive Clinical Outcomes 3Curemark CEO Presents at Epigenomics Conference 2
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, ... surgeon, Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of ... including Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... within the weekend edition of USA TODAY. This 12-page, glossy, full-color special section ... Today in highly targeted markets totaling approximately 450,000 copies, with an estimated readership ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The device is the first ... an alternative to continuous positive airway pressure (CPAP), the current standard of care ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... the independent auditor of customer service for the 40-center nursing home group. Sixteen ... skilled nursing centers in the United States in one or more customer service ...
(Date:6/29/2015)... Delaware (PRWEB) , ... June 29, 2015 , ... With ... Master® announces a partnership with the American Board of Urgent Care Medicine and the ... PRA Category 1 Credit™ to Urgent Care physicians and health care professionals. , According ...
Breaking Medicine News(10 mins):Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3
... Intelligent Order Routing allows hospital pharmacies to design their ... , , ROSEMONT, Ill., June 15 ... Inc., (Nasdaq: OMCL ) a leading provider ... the Omnicell WorkflowRx (TM) 6.0 central ...
... UTRECHT, The Netherlands, June 15 The largest global,study ... that strongly connected people have more enjoyment in their ... but more successful. Strongly,connected people have a better idea ... achieve it. The study, carried out by &intoconnection, proves ...
... HILLS, Mass., June 15 Joseph F. Finn, Jr., C.P.A. ("Finn") ... to and blocks the effects of galectin-3. Galectin-3 plays an ... proliferation and tumor metastasis, which is the spread of cancer beyond ... have multiple benefits in combating cancer cells, including: , , ...
... software platform and internal support for DailyMed Pharmacy , ... debt , , INDIANAPOLIS, June 15 Arcadia Resources, ... of home care, medical staffing, and pharmacy services under the ... retail pharmacy management software business. , , Arcadia ...
... and Media , , PHILADELPHIA, June 15 , , ... assistance and international healthcare, and provider of pandemic, ... companies, around the globe:, ... outbreak and, pandemic specialist, ...
... ... of 2009 "Best in KLAS" vendors , ... Orem, UT (PRWEB) June 15, 2009 -- Healthcare research firm ... in seven key market categories - including computed tomography (CT), digital mammography, smart pumps ...
Cached Medicine News:Health News:Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software 2Health News:Omnicell Boosts Pharmacy Efficiency with Enhanced WorkflowRx(TM) Central Pharmacy Automation Software 3Health News:Scientific Study Makes it Possible to Measure Connection Between People 2Health News:Scientific Study Makes it Possible to Measure Connection Between People 3Health News:Prospect Therapeutics' In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3 2Health News:Arcadia Resources Sells Non-Core Software Business 2Health News:Arcadia Resources Sells Non-Core Software Business 3Health News:Doctor, Pandemic Planning Expert to Host Webinar on Influenza H1N1 2Health News:Doctor, Pandemic Planning Expert to Host Webinar on Influenza H1N1 3Health News:Doctor, Pandemic Planning Expert to Host Webinar on Influenza H1N1 4Health News:Top-Performing Medical Equipment Companies Announced 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: